Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$36.06 +2.0%	$31.92	$23.42 ▼ $62.58	$2.09B	0.73	653,612 shs	258,713 shs
ALKS Alkermes	$28.75 -0.9%	$30.12	$22.90 ▼ $36.45	$4.76B	0.44	1.74 million shs	1.12 million shs
APLS Apellis Pharmaceuticals	$17.99 +0.9%	$18.15	$16.10 ▼ $42.47	$2.29B	0.67	2.35 million shs	891,120 shs
AXSM Axsome Therapeutics	$105.36 +1.4%	$106.63	$72.21 ▼ $139.13	$5.19B	0.46	669,187 shs	245,787 shs
ZLAB Zai Lab	$36.43 +2.6%	$33.80	$16.01 ▼ $44.34	$4.04B	0.99	914,335 shs	581,960 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	+7.72%	+7.37%	+39.97%	-14.20%
ALKS Alkermes	0.00%	-0.21%	-7.26%	-4.36%	+18.65%
APLS Apellis Pharmaceuticals	0.00%	+3.18%	-5.84%	-9.94%	-49.21%
AXSM Axsome Therapeutics	0.00%	+1.93%	-4.79%	+6.57%	+31.35%
ZLAB Zai Lab	0.00%	+4.86%	-0.30%	+14.67%	+111.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.0944 of 5 stars	3.4	1.0	4.3	1.9	0.8	1.9
ALKS Alkermes	4.9356 of 5 stars	4.4	3.0	4.2	3.4	2.5	1.9
APLS Apellis Pharmaceuticals	4.4251 of 5 stars	4.3	1.0	4.4	1.9	2.5	0.6
AXSM Axsome Therapeutics	4.7394 of 5 stars	4.5	1.0	4.5	2.3	4.2	0.6
ZLAB Zai Lab	3.4368 of 5 stars	3.4	5.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.71	Moderate Buy	$58.60	62.53% Upside
ALKS Alkermes	2.83	Moderate Buy	$40.00	39.13% Upside
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$39.79	121.24% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	63.57% Upside
ZLAB Zai Lab	2.80	Moderate Buy	$54.28	48.98% Upside

Current Analyst Ratings Breakdown

Latest AGIO, AXSM, ZLAB, APLS, and ALKS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/30/2025	ZLAB Zai Lab	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$73.00 ➝ $75.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	57.21	N/A	N/A	$27.02 per share	1.33
ALKS Alkermes	$1.56B	3.04	$2.64 per share	10.88	$9.05 per share	3.18
APLS Apellis Pharmaceuticals	$775.84M	2.91	N/A	N/A	$1.84 per share	9.77
AXSM Axsome Therapeutics	$432.16M	12.00	N/A	N/A	$1.18 per share	89.28
ZLAB Zai Lab	$398.99M	10.14	N/A	N/A	$7.68 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.24	3.21	N/A	N/A	1,798.26%	-2.75%	-2.52%	7/30/2025 (Estimated)
ALKS Alkermes	$367.07M	$2.09	13.76	20.99	1.79	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	37.36	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/5/2025 (Estimated)

Latest AGIO, AXSM, ZLAB, APLS, and ALKS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	-$1.55	+$0.25	-$1.55	$9.86 million	$8.73 million
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	18.50	17.93
ALKS Alkermes	N/A	3.33	2.92
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
AXSM Axsome Therapeutics	3.48	2.03	1.96
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ALKS Alkermes	95.21%
APLS Apellis Pharmaceuticals	96.29%
AXSM Axsome Therapeutics	81.49%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
ALKS Alkermes	4.40%
APLS Apellis Pharmaceuticals	6.50%
AXSM Axsome Therapeutics	22.30%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	57.92 million	55.43 million	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

AGIO, AXSM, ZLAB, APLS, and ALKS Headlines

Recent News About These Companies

Principal Financial Group Inc. Purchases 1,121,856 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 5 at 5:30 AM | marketbeat.com

Brokerages Set Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Target Price at $54.28

July 5 at 2:55 AM | americanbankingnews.com

Zai Lab FY2025 EPS Estimate Decreased by Cantor Fitzgerald

July 4 at 2:37 AM | americanbankingnews.com

Ying Du Sells 7,072 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

July 3 at 6:41 PM | marketbeat.com

Cantor Fitzgerald Lowers Earnings Estimates for Zai Lab

July 3 at 7:27 AM | marketbeat.com

FY2026 EPS Estimates for Zai Lab Raised by Leerink Partnrs

July 3 at 2:59 AM | americanbankingnews.com

Leerink Partnrs Analysts Lift Earnings Estimates for Zai Lab

July 2, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of Stock

July 2, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in Stock

July 1, 2025 | marketbeat.com

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint

July 1, 2025 | finance.yahoo.com

Amgen, Zai Lab succeed in gastric cancer study

June 30, 2025 | msn.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by Analysts

June 30, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Price Target Raised to $75.00 at Leerink Partners

June 30, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 30, 2025 | marketbeat.com

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

June 30, 2025 | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $855,160.97 in Stock

June 30, 2025 | americanbankingnews.com

Oppenheimer Asset Management Inc. Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 30, 2025 | marketbeat.com

Zai Lab (ZLAB) chief legal officer sells $212k in shares

June 29, 2025 | investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $96,647.75 in Stock

June 28, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

June 28, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Lowered by Wall Street Zen

June 28, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO, AXSM, ZLAB, APLS, and ALKS Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$36.06 +0.71 (+1.99%)

Closing price 07/3/2025 01:04 PM Eastern

Extended Trading

$36.06 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alkermes NASDAQ:ALKS

$28.75 -0.25 (-0.86%)

Closing price 07/3/2025 03:26 PM Eastern

Extended Trading

$28.75 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Apellis Pharmaceuticals NASDAQ:APLS

$17.98 +0.17 (+0.93%)

Closing price 07/3/2025 03:48 PM Eastern

Extended Trading

$17.93 -0.05 (-0.31%)

As of 07/3/2025 04:48 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Axsome Therapeutics NASDAQ:AXSM

$105.36 +1.45 (+1.39%)

Closing price 07/3/2025 02:04 PM Eastern

Extended Trading

$105.42 +0.06 (+0.06%)

As of 07/3/2025 04:42 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Zai Lab NASDAQ:ZLAB

$36.43 +0.94 (+2.65%)

Closing price 07/3/2025 02:41 PM Eastern

Extended Trading

$36.43 0.00 (0.00%)

As of 07/3/2025 04:34 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time